Filopodia powered by class X myosin promote fusion of mammalian myoblasts

  1. David W Hammers
  2. Cora C Hart
  3. Michael K Matheny
  4. Ernest G Heimsath
  5. Young il Lee
  6. John A Hammer III
  7. Richard E Cheney
  8. H Lee Sweeney  Is a corresponding author
  1. University of Florida, United States
  2. University of North Carolina, United States
  3. National Heart, Lung and Blood Institute, United States
  4. University of North Carolina School of Medicine, United States

Abstract

Skeletal muscle fibers are multinucleated cellular giants formed by the fusion of mononuclear myoblasts. Several molecules involved in myoblast fusion have been discovered, and finger-like projections coincident with myoblast fusion have also been implicated in the fusion process. The role of these cellular projections in muscle cell fusion was investigated herein. We demonstrate that these projections are filopodia generated by class X myosin (Myo10), an unconventional myosin motor protein specialized for filopodia. We further show that Myo10 is highly expressed by differentiating myoblasts, and Myo10 ablation inhibits both filopodia formation and myoblast fusion in vitro. In vivo, Myo10 labels regenerating muscle fibers associated with Duchenne muscular dystrophy and acute muscle injury. In mice, conditional loss of Myo10 from muscle-resident stem cells, known as satellite cells, severely impairs postnatal muscle regeneration. Furthermore, the muscle fusion proteins Myomaker and Myomixer are detected in myoblast filopodia. These data demonstrate that Myo10-driven filopodia facilitate multi-nucleated mammalian muscle formation.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided

Article and author information

Author details

  1. David W Hammers

    Department of Pharmacology and Therapeutics, University of Florida, Gainesville, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2129-4047
  2. Cora C Hart

    Department of Pharmacology and Therapeutics, University of Florida, Gainesville, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Michael K Matheny

    Department of Pharmacology and Therapeutics, University of Florida, Gainesville, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Ernest G Heimsath

    Cell Biology & Physiology, University of North Carolina, Chapel Hill, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Young il Lee

    Department of Pharmacology and Therapeutics, University of Florida, Gainesville, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. John A Hammer III

    Cell Biology and Physiology Center, National Heart, Lung and Blood Institute, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2496-5179
  7. Richard E Cheney

    Department of Cell Biology and Physiology, University of North Carolina School of Medicine, Chapel Hill, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6565-7888
  8. H Lee Sweeney

    Department of Pharmacology and Therapeutics, University of Florida, Gainesville, United States
    For correspondence
    lsweeney@ufl.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6290-8853

Funding

National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01-AR075637)

  • H Lee Sweeney

National Institute of Arthritis and Musculoskeletal and Skin Diseases (U54-AR-052646)

  • H Lee Sweeney

Fondation Leducq (13CVD04)

  • H Lee Sweeney

Muscular Dystrophy Association (MDA549004)

  • David W Hammers

National Institute of General Medical Sciences (R01-GM134531)

  • Richard E Cheney

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols of the University of Florida. Protocol #201910602.

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 1,527
    views
  • 258
    downloads
  • 13
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. David W Hammers
  2. Cora C Hart
  3. Michael K Matheny
  4. Ernest G Heimsath
  5. Young il Lee
  6. John A Hammer III
  7. Richard E Cheney
  8. H Lee Sweeney
(2021)
Filopodia powered by class X myosin promote fusion of mammalian myoblasts
eLife 10:e72419.
https://doi.org/10.7554/eLife.72419

Share this article

https://doi.org/10.7554/eLife.72419

Further reading

    1. Cell Biology
    Yue Miao, Yongtao Du ... Mei Ding
    Research Article

    The spatiotemporal transition of small GTPase Rab5 to Rab7 is crucial for early-to-late endosome maturation, yet the precise mechanism governing Rab5-to-Rab7 switching remains elusive. USP8, a ubiquitin-specific protease, plays a prominent role in the endosomal sorting of a wide range of transmembrane receptors and is a promising target in cancer therapy. Here, we identified that USP8 is recruited to Rab5-positive carriers by Rabex5, a guanine nucleotide exchange factor (GEF) for Rab5. The recruitment of USP8 dissociates Rabex5 from early endosomes (EEs) and meanwhile promotes the recruitment of the Rab7 GEF SAND-1/Mon1. In USP8-deficient cells, the level of active Rab5 is increased, while the Rab7 signal is decreased. As a result, enlarged EEs with abundant intraluminal vesicles accumulate and digestive lysosomes are rudimentary. Together, our results reveal an important and unexpected role of a deubiquitinating enzyme in endosome maturation.

    1. Cancer Biology
    2. Cell Biology
    Kourosh Hayatigolkhatmi, Chiara Soriani ... Simona Rodighiero
    Tools and Resources

    Understanding the cell cycle at the single-cell level is crucial for cellular biology and cancer research. While current methods using fluorescent markers have improved the study of adherent cells, non-adherent cells remain challenging. In this study, we addressed this gap by combining a specialized surface to enhance cell attachment, the FUCCI(CA)2 sensor, an automated image analysis pipeline, and a custom machine learning algorithm. This approach enabled precise measurement of cell cycle phase durations in non-adherent cells. This method was validated in acute myeloid leukemia cell lines NB4 and Kasumi-1, which have unique cell cycle characteristics, and we tested the impact of cell cycle-modulating drugs on NB4 cells. Our cell cycle analysis system, which is also compatible with adherent cells, is fully automated and freely available, providing detailed insights from hundreds of cells under various conditions. This report presents a valuable tool for advancing cancer research and drug development by enabling comprehensive, automated cell cycle analysis in both adherent and non-adherent cells.